nach oben

Current Psychiatry Reports

Erschienen in:

01.09.2014 | Geriatric Disorders (W McDonald, Section Editor)

Current Understanding of the Neurobiology and Longitudinal Course of Geriatric Depression

verfasst von: Sara L. Weisenbach, Anand Kumar

Erschienen in: Current Psychiatry Reports | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Late life depression is a complex disease associated with a number of contributing neurobiological factors, including cerebrovascular disease, neurodegeneration, and inflammation, which also contribute to its longitudinal prognosis and course. These factors create a context in which the brain is more vulnerable to the impact of stress, and thus, to depression. At the same time, some individuals are protected from late life depression and its consequences, even in the face of neurobiological vulnerability, through benefitting from one or more attributes associated with resilience, including social support, engagement in physical and cognitive activities, and brain reserve. Enhanced understanding of how neurobiological and environmental factors interact in predicting vulnerability and resilience is needed to predict onset and course of depression in late life and develop more effective interventions.

Bruce ML, Seeman TE, Merrill SS, Blazer DG. The impact of depressive symptomatology on physical disability: MacArthur Studies of Successful Aging. Am J Public Health. 1994;84:1796–9.PubMedCentralPubMedCrossRef

Bruce ML. Depression and disability in late life: directions for future research. Am J Geriatr Psychiatry. 2001;9:102–12.PubMedCrossRef

Gallo JJ, Bogner HR, Morales KH, et al. The effect of a primary care practice-based depression intervention on mortality in older adults: a randomized trial. Ann Intern Med. 2007;146:689–98.PubMedCentralPubMedCrossRef

Sheeran T, Brown EL, Nassisi P, Bruce ML. Does depression predict falls among home health patients? Using a clinical-research partnership to improve the quality of geriatric care. Home Healthc Nurse. 2004;22:384–9.PubMedCrossRef

Voaklander DC, Rowe BH, Dryden DM, et al. Medical illness, medication use and suicide in seniors: a population-based case-control study. J Epidemiol Community Health. 2008;62:138–46.PubMedCrossRef

Alexopoulos GS. Depression in the elderly. Lancet. 2005;365:1961–70.PubMedCrossRef

Aizenstein HJ, Butters MA, Figurski JL, et al. Prefrontal and striatal activation during sequence learning in geriatric depression. Biol Psychiatry. 2005;58:290–6.PubMedCrossRef

Aizenstein HJ, Butters MA, Wu M, et al. Altered functioning of the executive control circuit in late-life depression: episodic and persistent phenomena. Am J Geriatr Psychiatry. 2009;17:30–42.PubMedCentralPubMedCrossRef

Post F. The significance of affective disorders in old age. London: Institute of Psychiatry; 1962. Maudsley Monograph.

10.

Post F, Schulman K. New views on old age affective disorder. In: Aire T, editor. Recent advances in psychogeriatrics. New York: Churchill Livingstone Inc; 1985. p. 119–40.

11.

Alexopoulos GS. “The depression-executive dysfunction syndrome of late life”: a specific target for D3 agonists? Am J Geriatr Psychiatry. 2001;9:22–9.PubMed

12.

Alexopoulos GS. Frontostriatal and limbic dysfunction in late-life depression. Am J Geriatr Psychiatry. 2002;10:687–95.PubMedCrossRef

13.

Krishnan KR, Hays JC, Blazer DG. MRI-defined vascular depression. Am J Psychiatry. 1997;154:497–501.PubMed

14.

Krishnan KR, Taylor WD, McQuoid DR, et al. Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. Biol Psychiatry. 2004;55:390–7.PubMedCrossRef

15.

Alexopoulos GS, Meyers BS, Young RC, et al. ‘Vascular depression’ hypothesis. Arch Gen Psychiatry. 1997;54:915–22.PubMedCrossRef

16.••

Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry. 2013;18:963–74. This seminal review of the vascular depression literature proposes three mechanisms mediating the relationship between vascular disease and depression in late life, including disconnection, hypoperfusion, and inflammation.PubMedCentralPubMedCrossRef

17.•

Lamar M, Charlton RA, Ajilore O, et al. Prefrontal vulnerabilities and whole brain connectivity in aging and depression. Neuropsychologia. 2013;51:1463–70. Healthy older adults exhibited a significant relationship between white matter network vulnerability as measured using diffusion tensor imaging fractional anisotropy (FA) and performance on the Object Alteration Task. This relationship was not present in older depressed individuals, in which a significant relationship was observed only in FA of the uncinate fasciculus and task performance. The authors conclude that whole brain impact of vulnerabilities in fronto-limbic networks associated with aging may be obscured in the context of disease, such as depression. PubMedCentralPubMedCrossRef

18.

Smith EE, Salat DH, Jeng J, et al. Correlations between MRI white matter lesion location and executive function and episodic memory. Neurology. 2011;76:1492–9.PubMedCentralPubMedCrossRef

19.

Dalby RB, Frandsen J, Chakravarty MM, et al. Depression severity is correlated to the integrity of white matter fiber tracts in late-onset major depression. Psychiatry Res. 2010;184:38–48.PubMedCrossRef

20.

de Groot E, Hovingh GK, Wiegman A, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation. 2004;109(23 Suppl 1):III33–8.PubMed

21.

Wong M, Edelstein J, Wollman J, Bond MG. Ultrasonic-pathological comparison of the human arterial wall. Verification of intima-media thickness. Arterioscler Thromb. 1993;13:482–6.PubMedCrossRef

22.

Chen CS, Chen CC, Kuo YT, et al. Carotid intima-media thickness in late-onset major depressive disorder. Int J Geriatr Psychiatry. 2006;21:36–42.PubMedCrossRef

23.

Smith PJ, Blumenthal JA, Babyak MA, et al. Intima-media thickness and age of first depressive episode. Biol Psychol. 2009;80:361–4.PubMedCentralPubMedCrossRef

24.

Paranthaman R, Greenstein A, Burns AS, et al. Relationship of endothelial function and atherosclerosis to treatment response in late-life depression. Int J Geriatr Psychiatry. 2012;27:967–73.PubMedCrossRef

25.

Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23:7–17.PubMedCrossRef

26.

Di Napoli M, Papa F. C-reactive protein and cerebral small-vessel disease: an opportunity to reassess small-vessel disease physiopathology? Circulation. 2005;112:781–5.PubMedCrossRef

27.

Greenstein AS, Paranthaman R, Burns A, et al. Cerebrovascular damage in late-life depression is associated with structural and functional abnormalities of subcutaneous small arteries. Hypertension. 2010;56:734–40.PubMedCrossRef

28.

Paranthaman R, Greenstein AS, Burns AS, et al. Vascular function in older adults with depressive disorder. Biol Psychiatry. 2010;68:133–9.PubMedCrossRef

29.•

Direk N, Koudstaal PJ, Hofman A, et al. Cerebral hemodynamics and incident depression: the Rotterdam Study. Biol Psychiatry. 2012;72:318–23. In a large cohort of older adults from the Rotterdam Study, lower blood flow velocity (a proxy for cerebral metabolism), was associated with depressive symptoms and disorders. Reduced vasomotor activity (suggestive of cerebral microangiopathy), was associated with depressive disorders.PubMedCrossRef

30.

Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol. 2011;7:323–31.PubMedCentralPubMedCrossRef

31.••

Diniz BS, Butters MA, Albert SM, et al. Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202:329–35. A meta-analysis of 23 studies to calculate the pooled risk of dementia in late life depression resulted in odds ratios of 1.85 for all cause dementia,1.65 for Alzheimer’s disease, and 2.52 for vascular dementia, respectively.PubMedCentralPubMedCrossRef

32.

Geerlings MI, den Heijer T, Koudstaal PJ, et al. History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology. 2008;70:1258–64.PubMedCrossRef

33.

Kumar A, Bilker W, Jin Z, Udupa J. Atrophy and high intensity lesions: complementary neurobiological mechanisms in late-life major depression. Neuropsychopharmacology. 2000;22:264–74.PubMedCrossRef

34.••

Sexton CE, Mackay CE, Ebmeier KP. A systematic review and meta-analysis of magnetic resonance imaging studies in late-life depression. Am J Geriatr Psychiatry. 2013;21:184–95. A meta-analysis of 17 studies investigating gray matter volumes in late life depression found significantly lower volumes in hippocampus, orbitofrontal cortex, putamen, and thalamus among depressed relative to non-depressed comparison participants.PubMedCrossRef

35.

Steffens DC, Byrum CE, McQuoid DR, et al. Hippocampal volume in geriatric depression. Biol Psychiatry. 2000;48:301–9.PubMedCrossRef

36.•

Zahodne LB, Gongvatana A, Cohen RA, Ott BR, Tremont G. Are apathy and depression independently associated with longitudinal trajectories of cortical atrophy in mild cognitive impairment? Am J Geriatr Psychiatry. 2013;21:1098–106. Using a sample of 334 participants with Mild Cognitive Impairment (MCI) from the Alzheimer’s Disease Neuroimaging Initiative Study, investigators found that depression was associated with less cortical thickness in the entorhinal cortex at baseline and greater atrophy over the study period (M = 30.5 months). Apathy was not predictive of cortical thickness in any region measured at baseline or over the study period. Findings suggest that in patients with MCI, depression may be a stronger predictor of longitudinal cortical atrophy than apathy.PubMedCrossRef

37.

Sweet RA, Hamilton RL, Butters MA, et al. Neuropathologic correlates of late-onset major depression. Neuropsychopharmacology. 2004;29:2242–50.PubMedCrossRef

38.

Beekman AT. Neuropathological correlates of late-life depression. Expert Rev Neurother. 2011;11:947–9.PubMedCrossRef

39.

Thomas AJ, Ferrier IN, Kalaria RN, et al. A neuropathological study of vascular factors in late-life depression. J Neurol Neurosurg Psychiatry. 2001;70:83–7.PubMedCentralPubMedCrossRef

40.

Rapp MA, Schnaider-Beeri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry. 2006;63:161–7.PubMedCrossRef

41.

Butters MA, Klunk WE, Mathis CA, et al. Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord. 2008;22:261–8.PubMedCentralPubMedCrossRef

42.

Kumar A, Kepe V, Barrio JR, et al. Protein binding in patients with late-life depression. Arch Gen Psychiatry. 2011;68:1143–50.PubMedCentralPubMedCrossRef

43.

Wu C, Pike VW, Wang Y. Amyloid imaging: from benchtop to bedside. Curr Top Dev Biol. 2005;70:171–213.PubMedCrossRef

44.•

Madsen K, Hasselbalch BJ, Frederiksen KS, et al. Lack of association between prior depressive episodes and cerebral [11C]PiB binding. Neurobiol Aging. 2012;33:2334–42. Older adults with remitted depression were equivalent to never-depressed comparisons in [11C]PiB binding, but did demonstrate more severe white matter lesions. There were no associations between PiB binding and number of depressive episodes, cognitive performance, or antidepressant treatment. The authors conclude that their findings suggest that history of depression may not be associated with development of Alzheimer’s disease.PubMedCrossRef

45.

Pomara N, Willoughby LM, Sidtis JJ, Mehta PD. Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry. 2005;13:914–7.PubMed

46.

Schupf N, Tang MX, Fukuyama H, et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer’s disease. Proc Natl Acad Sci. 2008;105:14052–7.PubMedCentralPubMedCrossRef

47.

Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512–9.PubMedCrossRef

48.

Pomara N, Doraiswamy PM, Willoughby LM, et al. Elevation in plasma Abeta42 in geriatric depression: a pilot study. Neurochem Res. 2006;31:341–9.PubMedCrossRef

49.

Osorio RS, Gumb T, Pomara N. Soluble amyloid-beta levels and late-life depression. Curr Pharm Des. 2014;20:2547–54.PubMedCentralPubMed

50.

Blasko I, Kemmler G, Jungwirth S, et al. Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. Am J Geriatr Psychiatry. 2010;18:973–82.PubMedCrossRef

51.

Sun X, Steffens DC, Au R, et al. Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry. 2008;65:542–50.PubMedCentralPubMedCrossRef

52.•

Pomara N, Bruno D, Sarreal AS, et al. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry. 2012;169:523–30. In a sample of 47 non-demented older adults, CSF Aβ42 levels were significantly lower and isoprostane levels were significantly higher among those with Major Depressive Disorder relative to the healthy comparison group. There were no group differences in measures of CSF tau. The authors conclude that the reduction in CSF amyloid beta levels in older adults with depression may be due to increased brain beta amyloid plaques or decreased soluble amyloid beta production.PubMedCentralPubMedCrossRef

53.

Gudmundsson P, Skoog I, Waern M, et al. The relationship between cerebrospinal fluid biomarkers and depression in elderly women. Am J Geriatr Psychiatry. 2007;15:832–8.PubMedCrossRef

54.

Buerger K, Zinkowski R, Teipel SJ, et al. Differentiation of geriatric major depression from Alzheimer’s disease with CSF tau protein phosphorylated at threonine 231. Am J Psychiatry. 2003;160:376–9.PubMedCrossRef

55.

Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991;12:383–8.PubMedCrossRef

56.

Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med. 2011;73:114–26.PubMedCrossRef

57.

Wolf OT, Convit A, de Leon MJ, et al. Basal hypothalamo-pituitary-adrenal axis activity and corticotropin feedback in young and older men: relationships to magnetic resonance imaging-derived hippocampus and cingulate gyrus volumes. Neuroendocrinology. 2002;75:241–9.PubMedCrossRef

58.

Green KN, Billings LM, Roozendaal B, et al. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer’s disease. J Neurosci. 2006;26:9047–56.PubMedCrossRef

59.

Dong H, Yuede CM, Yoo HS, et al. Corticosterone and related receptor expression are associated with increased beta-amyloid plaques in isolated Tg2576 mice. Neuroscience. 2008;155:154–63.PubMedCentralPubMedCrossRef

60.

Kang JE, Cirrito JR, Dong H, et al. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A. 2007;104:10673–8.PubMedCentralPubMedCrossRef

61.

Alexopoulos GS, Morimoto SS. The inflammation hypothesis in geriatric depression. Int J Geriatr Psychiatry. 2011;26:1109–18.PubMedCentralPubMed

62.•

Baune BT, Smith E, Reppermund S, et al. Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney Memory and Aging Study. Psychoneuroendocrinology. 2012;37:1521–30. Among 1037- non-demented community volunteers, IL-6 and IL-8 levels were associated with depressive symptoms at baseline. IL-8 levels were additionally associated with depressive symptoms at two-year follow-up and the onset of mild to moderate depression over two years. PAI-I was related to remitted depression, and there was no relationship with cytokine levels and anxiety symptoms.PubMedCrossRef

63.

Bremmer MA, Beekman AT, Deeg DJ, et al. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord. 2008;106:249–55.PubMedCrossRef

64.

Dentino AN, Pieper CF, Rao MK, et al. Association of interleukin-6 and other biologic variables with depression in older people living in the community. J Am Geriatr Soc. 1999;47:6–11.PubMed

65.

Dimopoulos N, Piperi C, Psarra V, et al. Increased plasma levels of 8-iso-PGF2alpha and IL-6 in an elderly population with depression. Psychiatry Res. 2008;161:59–66.PubMedCrossRef

66.

Forti P, Rietti E, Pisacane N, et al. Blood inflammatory proteins and risk of incident depression in the elderly. Dement Geriatr Cogn Disord. 2010;29:11–20.PubMedCrossRef

67.

Matheny ME, Miller RR, Shardell MD, et al. Inflammatory cytokine levels and depressive symptoms in older women in the year after hip fracture: findings from the Baltimore Hip Studies. J Am Geriatr Soc. 2011;59:2249–55.PubMedCentralPubMedCrossRef

68.

Milaneschi Y, Corsi AM, Penninx BW, et al. Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI study. Biol Psychiatry. 2009;65:973–8.PubMedCentralPubMedCrossRef

69.

Penninx BW, Kritchevsky SB, Yaffe K, et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatry. 2003;54:566–72.PubMedCrossRef

70.

Naude PJ, Eisel UL, Comijs HC, et al. Neutrophil gelatinase-associated lipocalin: a novel inflammatory marker associated with late-life depression. J Psychosom Res. 2013;75:444–50.PubMedCrossRef

71.

Tiemeier H, Hofman A, van Tuijl HR, et al. Inflammatory proteins and depression in the elderly. Epidemiology. 2003;14:103–7.PubMedCrossRef

72.

Fornage M, Chiang YA, O’Meara ES, et al. Biomarkers of inflammation and MRI-defined small vessel disease of the brain: The Cardiovascular Health Study. Stroke. 2008;39:1952–9.PubMedCentralPubMedCrossRef

73.•

Raz N, Yang Y, Dahle CL, Land S. Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants. Biochim Biophys Acta. 1822;2012:361–9. Among 144 healthy older adults, larger white matter hyperintensity volume was associated with age, hypertension, and elevated levels of homocysteine and C-reactive protein, but not with low-density lipoprotein levels. Individuals with genetic variants protomoting inflammation had greater volume of white matter hyperintensities than those who did not.

74.

Satizabal CL, Zhu YC, Mazoyer B, et al. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology. 2012;78:720–7.PubMedCrossRef

75.

van Dijk EJ, Prins ND, Vermeer SE, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation. 2005;112:900–5.PubMedCrossRef

76.•

Elderkin-Thompson V, Irwin MR, Hellemann G, Kumar A. Interleukin-6 and memory functions of encoding and recall in healthy and depressed elderly adults. Am J Geriatr Psychiatry. 2012;20:753–63. Performance on a memory measure was associated with IL-6 levels among depressed and non-depressed older adults. Older adults with depression had poorer recall than comparisons, independent of IL-6 levels.PubMedCentralPubMedCrossRef

77.

Maes M, Leonard BE, Myint AM, et al. The new ‘5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:702–21.PubMedCrossRef

78.

O’Connor JC, Andre C, Wang Y, et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci. 2009;29:4200–9.PubMedCentralPubMedCrossRef

79.

O’Connor JC, Lawson MA, Andre C, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry. 2009;14:511–22.PubMedCentralPubMedCrossRef

80.

Stone TW, Behan WM. Interleukin-1beta but not tumor necrosis factor-alpha potentiates neuronal damage by quinolinic acid: protection by an adenosine A2A receptor antagonist. J Neurosci Res. 2007;85:1077–85.PubMedCrossRef

81.

Koo JW, Duman RS. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A. 2008;105:751–6.PubMedCentralPubMedCrossRef

82.

Leonard BE. Inflammation, depression and dementia: are they connected? Neurochem Res. 2007;32:1749–56.PubMedCrossRef

83.

Hermida AP, McDonald WM, Steenland K, Levey A. The association between late-life depression, mild cognitive impairment and dementia: is inflammation the missing link? Expert Rev Neurother. 2012;12:1339–50.PubMedCrossRef

84.••

Wirth M, Villeneuve S, Haase CM, et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol. 2013;70:1512–9. 40 % of cognitively normal older adults with no evidence of elevated PiB binding displayed at least one abnormal neurodegernative biomarker (i.e., hippocampal volume, glucose metabolism, and grath matter thickness). Individuals with abnormal cortical thickness had neurodegenerative abnormalities that were similar to patients with Alzheimer’s disease. Greater neurodegenerative abnormalities were associated with poorer memory and executive functioning performance, but not greater PiB binding.

85.

Adams KB, Sanders S, Auth EA. Loneliness and depression in independent living retirement communities: risk and resilience factors. Aging Ment Health. 2004;8:475–85.PubMedCrossRef

86.

Prince MJ, Harwood RH. Thomas A, Mann AH: A prospective population-based cohort study of the effects of disablement and social milieu on the onset and maintenance of late-life depression. The Gospel Oak Project VII. Psychol Med. 1998;28:337–50.PubMedCrossRef

87.

Yang Y. How does functional disability affect depressive symptoms in late life? The role of perceived social support and psychological resources. J Health Soc Behav. 2006;47:355–72.PubMedCrossRef

88.

Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10:819–28.PubMedCentralPubMedCrossRef

89.•

Wirth M, Haase CM, Villeneuve S, et al. Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults. Neurobiol Aging. 2014;35:1873–82. Among 92 cognitively normal older adults, higher lifetime cognitive activity and higher current physical activity were associated with fewer white matter lesions, which were, in turn, associated with a higher composite measure of global integrity and higher cognitive functioning. Higher lifetime cognitive activity predicted lower PiB retention, which moderated the relationship between neural integiry and cognition. It is concluded that lifetime cognitive and current physical activity may decrease the development of dementia by protecting against cerebrovascular and A beta pathology.PubMedCrossRef

90.

Blake H, Mo P, Malik S, Thomas S. How effective are physical activity interventions for alleviating depressive symptoms in older people? A systematic review. Clin Rehabil. 2009;23:873–87.PubMedCrossRef

91.

Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc. 2002;8:448–60.PubMedCrossRef

92.••

Amieva H, Mokri H, Le Goff M, et al. Compensatory mechanisms in higher-educated subjects with Alzheimer’s disease: a study of 20 years of cognitive decline. Brain. 2014;137(Pt 4):1167–75. Over a 20-year period, cognition among 442 people with incident Alzheimer’s disease were assessed. Cognitive symptoms emerge up to 16 years preceding conversion to dementia in high and low educated individuals, but among those with low education, more immediately converted to dementia, whereas conversion was slower among those with higher levels of education.

93.

Osone A, Arai R, Hakamada R, Shimoda K. Impact of cognitive reserve on the progression of mild cognitive impairment to Alzheimer’s disease in Japan. Geriatr Gerontol Int. 2014. doi:10.1111/ggi.12292.PubMed

94.

Stern Y. Cognitive reserve. Neuropsychologia. 2009;47:2015–28.PubMedCentralPubMedCrossRef

95.•

Paulson D, Bowen ME, Lichtenberg PA. Does brain reserve protect older women from vascular depression? J Gerontol B Psychol Sci Soc Sci. 2014;69:157–67. Among 1355 older women, higher level of education and lower cerebrovascular burden were negatively associated with depressive symptoms at baseline, but over six years, the protective effect of education on depressive symptoms decreased.PubMed

Titel: Current Understanding of the Neurobiology and Longitudinal Course of Geriatric Depression
verfasst von: Sara L. Weisenbach
Anand Kumar
Publikationsdatum: 01.09.2014
Verlag: Springer US
Erschienen in: Current Psychiatry Reports / Ausgabe 9/2014
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI: https://doi.org/10.1007/s11920-014-0463-y

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2014

Adolescents and the Internet: What Mental Health Clinicians Need to Know

Meta-Analytic Review of Psychological Interventions for Children Survivors of Natural and Man-Made Disasters

Suicide Risk in Primary Care: Identification and Management in Older Adults

Self-Management and Bipolar Disorder–A Clinician’s Guide to the Literature 2011-2014